Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 over exp PIK3CA H1047R |
| Therapy | Buparlisib + Pertuzumab |
| Indication/Tumor Type | breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 over exp PIK3CA H1047R | breast cancer | sensitive | Buparlisib + Pertuzumab | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a breast cancer cell line xenograft model harboring ERBB3 (HER3) over expression and PIK3CA H1047R in brain metastases was sensitive to the combined treatment of Buparlisib (BKM120) and Perjeta (pertuzumab), demonstrating delayed tumor growth and better survival when compared to either treatment alone (PMID: 28539475). | 28539475 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28539475) | The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. | Full reference... |